BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25963480)

  • 1. Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype.
    Unruh D; Sagin F; Adam M; Van Dreden P; Woodhams BJ; Hart K; Lindsell CJ; Ahmad SA; Bogdanov VY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1206-11. PubMed ID: 25963480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.
    Unruh D; Turner K; Srinivasan R; Kocatürk B; Qi X; Chu Z; Aronow BJ; Plas DR; Gallo CA; Kalthoff H; Kirchhofer D; Ruf W; Ahmad SA; Lucas FV; Versteeg HH; Bogdanov VY
    Int J Cancer; 2014 Jan; 134(1):9-20. PubMed ID: 23754313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternatively spliced tissue factor levels are elevated in the plasma of patients with chronic liver diseases.
    Caversaccio NI; Reina Caro MD; Prince R; Müller M; Lewis CS; Bogdanov VY; Dufour JF; Angelillo-Scherrer A
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1470-1475. PubMed ID: 30113368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.
    Unruh D; Ünlü B; Lewis CS; Qi X; Chu Z; Sturm R; Keil R; Ahmad SA; Sovershaev T; Adam M; Van Dreden P; Woodhams BJ; Ramchandani D; Weber GF; Rak JW; Wolberg AS; Mackman N; Versteeg HH; Bogdanov VY
    Oncotarget; 2016 May; 7(18):25264-75. PubMed ID: 26967388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions.
    Ramchandani D; Unruh D; Lewis CS; Bogdanov VY; Weber GF
    Lab Invest; 2016 Dec; 96(12):1234-1245. PubMed ID: 27721473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis.
    Signaevsky M; Hobbs J; Doll J; Liu N; Soff GA
    Semin Thromb Hemost; 2008 Mar; 34(2):161-9. PubMed ID: 18645921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells.
    Chand HS; Ness SA; Kisiel W
    Int J Cancer; 2006 Apr; 118(7):1713-20. PubMed ID: 16217771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
    Nitori N; Ino Y; Nakanishi Y; Yamada T; Honda K; Yanagihara K; Kosuge T; Kanai Y; Kitajima M; Hirohashi S
    Clin Cancer Res; 2005 Apr; 11(7):2531-9. PubMed ID: 15814630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of flTF and asTF splice variants in various cell strains and tissues.
    Pan L; Yu Y; Yu M; Yao S; Mu Q; Luo G; Xu N
    Mol Med Rep; 2019 Mar; 19(3):2077-2086. PubMed ID: 30664196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.
    Kolb A; Rieder S; Born D; Giese NA; Giese T; Rudofsky G; Werner J; Büchler MW; Friess H; Esposito I; Kleeff J
    Cancer Biol Ther; 2009 Aug; 8(16):1527-33. PubMed ID: 19571666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating IL-35 in pancreatic ductal adenocarcinoma patients.
    Jin P; Ren H; Sun W; Xin W; Zhang H; Hao J
    Hum Immunol; 2014 Jan; 75(1):29-33. PubMed ID: 24121041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.
    Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between alternatively spliced Tissue Factor and full length Tissue Factor in modulating coagulant activity of endothelial cells.
    Ünlü B; Bogdanov VY; Versteeg HH
    Thromb Res; 2017 Aug; 156():1-7. PubMed ID: 28570958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
    Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
    Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.
    Kocatürk B; Tieken C; Vreeken D; Ünlü B; Engels CC; de Kruijf EM; Kuppen PJ; Reitsma PH; Bogdanov VY; Versteeg HH
    J Thromb Haemost; 2015 Sep; 13(9):1683-93. PubMed ID: 26179105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.